DOCSLIB.ORG

761149Orig1s000 CLINICAL REVIEW(S)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
761149Orig1s000 CLINICAL REVIEW(S) CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761149Orig1s000 CLINICAL REVIEW(S) Clinical Review Lawrence Rodichok MD BLA 761149 Enspryng/satralizumab-mwge CLINICAL REVIEW Application Type BLA Application Number(s) 761149 Priority or Standard Standard Submit Date(s) 8/15/19 Received Date(s) 8/15/19 PDUFA Goal Date 8/15/2020 Division/Office DN2/Office of Neuroscience Reviewer Name(s) Lawrence Rodichok MD Review Completion Date 5/28/20 (b) (4) Established/Proper Name Satralizumab-mwge (Proposed) Trade Name Enspryng Applicant Roche/Genentech Dosage Form(s) Injection:120mg/mL in a single-dose prefilled syringe Applicant Proposed Dosing 120 mg subcutaneous at Weeks 0, 2 and 4, and every 4 weeks (Q4W) thereafter Regimen(s) (b) (4) Applicant Proposed Adult with Indication(s)/Population(s) NMOSD. Recommendation on Approval Regulatory Action Recommended The treatment of neuromyelitis optica spectrum disorder Indication(s)/Population(s) (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) (if applicable) antibody positive CDER Clinical Review Template 1 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4654184 Clinical Review Lawrence Rodichok MD BLA 761149 Enspryng/satralizumab-mwge Table of Contents Glossary ......................................................................................................................................... 11 1. Executive Summary ............................................................................................................... 14 Product Introduction ...................................................................................................... 14 Conclusions on the Substantial Evidence of Effectiveness ............................................ 14 Benefit-Risk Assessment ................................................................................................ 14 Patient Experience Data ................................................................................................. 17 2. Therapeutic Context .............................................................................................................. 19 Analysis of Condition ...................................................................................................... 19 Analysis of Current Treatment Options ......................................................................... 20 3. Regulatory Background ......................................................................................................... 22 U.S. Regulatory Actions and Marketing History ............................................................. 22 Summary of Presubmission/Submission Regulatory Activity ........................................ 22 Foreign Regulatory Actions and Marketing History ....................................................... 23 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety................................................................................................................. 23 Office of Scientific Investigations (OSI) .......................................................................... 23 Product Quality .............................................................................................................. 23 Clinical Microbiology ...................................................................................................... 23 Nonclinical Pharmacology/Toxicology ........................................................................... 23 Clinical Pharmacology .................................................................................................... 24 Devices and Companion Diagnostic Issues .................................................................... 24 Consumer Study Reviews ............................................................................................... 24 5. Sources of Clinical Data and Review Strategy ....................................................................... 24 Table of Clinical Studies .................................................................................................. 25 Review Strategy .............................................................................................................. 25 6. Review of Relevant Individual Trials Used to Support Efficacy ............................................. 25 Study 309JG; bn40900. A Multicenter, Randomized, Double-Blind, Placebo-controlled Study To Evaluate The Efficacy And Safety of Satralizumab-mwge (SA237) As Monotherapy In CDER Clinical Review Template 2 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4654184 Clinical Review Lawrence Rodichok MD BLA 761149 Enspryng/satralizumab-mwge Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optic Spectrum Disorder (NMOSD) ................................................................................................................................... 26 Study Design............................................................................................................ 26 Study Results ........................................................................................................... 35 6.2 Study 307JG; bn40898; A Multicenter, Randomized, Addition To Baseline Treatment, Double-Blind, Placebo-controlled, Phase 3 Study To Evaluate The Efficacy And Safety of Satralizumab-mwge (SA237) In Patients With Neuromyelitis Optica (NMO) And NMO Spectrum Disorder (NMOSD) .................................................................................................... 58 6.2.1 Study Design............................................................................................................ 58 6.2.2 Study Results ........................................................................................................... 62 7 Integrated Review of Effectiveness ....................................................................................... 86 7.2 Assessment of Efficacy Across Trials .............................................................................. 86 7.2.1 Primary Endpoints ................................................................................................... 86 7.2.2 Secondary and Other Endpoints ............................................................................. 86 7.2.3 Subpopulations ....................................................................................................... 86 7.2.4 Dose and Dose-Response........................................................................................ 86 7.2.5 Onset, Duration, and Durability of Efficacy Effects ................................................ 86 7.3 Additional Efficacy Considerations ................................................................................. 87 7.3.1 Considerations on Benefit in the Postmarket Setting ............................................ 87 7.3.2 Other Relevant Benefits .......................................................................................... 87 7.4 Integrated Assessment of Effectiveness ........................................................................ 87 8 Review of Safety .................................................................................................................... 87 8.2 Safety Review Approach ................................................................................................ 87 8.3 Review of the Safety Database ...................................................................................... 87 8.3.1 Overall Exposure ..................................................................................................... 87 8.3.2 Relevant characteristics of the safety population: ................................................. 88 8.3.3 Adequacy of the safety database: .......................................................................... 88 8.4 Adequacy of Applicant’s Clinical Safety Assessments .................................................... 88 8.4.1 Issues Regarding Data Integrity and Submission Quality ....................................... 89 8.4.2 Categorization of Adverse Events ........................................................................... 89 8.4.3 Routine Clinical Tests .............................................................................................. 89 CDER Clinical Review Template 3 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4654184 Clinical Review Lawrence Rodichok MD BLA 761149 Enspryng/satralizumab-mwge 8.5 Safety Results ................................................................................................................. 89 8.5.1 Deaths ..................................................................................................................... 89 8.5.2 Serious Adverse Events ........................................................................................... 89 8.5.3 Dropouts and/or Discontinuations Due to Adverse Effects ................................... 94 8.5.4 Significant Adverse Events ...................................................................................... 95 8.5.5 Treatment Emergent Adverse Events and Adverse Reactions ............................... 95 8.5.6 Laboratory Findings .............................................................................................. 104 8.5.7 Vital Signs .............................................................................................................. 121 8.5.8 Electrocardiograms
Load more

Recommended publications
  • Neuromyelitis Optica Spectrum Disorder
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder Date of Review: April 2021 Date of Last Review: n/a Dates of Literature Search: 1/1/1996 – 1/20/2021 Generic Name: Brand Name (Manufacturer): Eculizumab Soliris® (Alexion Pharmaceuticals) Inebilizumab-cdon Uplizna™ (Viela Bio) Satralizumab-mwge Enspryng™ (Genentech/Roche) Dossiers Received: Yes Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To define place in therapy for 3 immunosuppressive agents, eculizumab, inebilizumab-cdon, and satralizumab-mwge, recently approved by the Food and Drug Administration (FDA) for the treatment adults with neuromyelitis optica spectrum disorder (NMOSD). Research Questions: 1. What is the effectiveness of eculizumab, inebilizumab, and satralizumab in reducing time to relapse in adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive? 2. What are the harms of eculizumab, inebilizumab-cdon and satralizumab in adults with NMOSD? 3. Is there comparative evidence that eculizumab, inebilizumab, and satralizumab differ in efficacy or harms for management of NMOSD? 4. Are there certain sub-populations (based on age, gender, ethnicity, comorbidities, disease duration or severity) in which eculizumab, inebilizumab, or satralizumab may be beneficial
    [Show full text]
  • Neuromyelitis Optica News
    Neuromyelitis Optica News Gloria von Geldern, MD Assistant Professor of Neurology University of Washington Multiple Sclerosis Center Multiple Sclerosis Regional Summit June 13, 2020 Disclosures ▪ No conflict of interest ▪ Off-label treatments will be mentioned Current research funding Patient-Centered Outcomes Research Institute (PCORI) What is New in NMO? Natalia Rost, MD Chair scientific committee AAN Neuromyelitis Optica (NMO) Neuromyelitis Optica Spectrum Disease (NMOSD) ▪ Inflammatory disorder of the central nervous system ▪ Predominantly involving optic nerves and spinal cord ▪ Severe demyelination and axonal damage ▪ Rare disease: 0.5-10/100,000, ~8,000 patients in the US ▪ Black > Asian > White ▪ Female > Male Flanagan et al., 2016 Bukhari et al. 2017 Hor et al. 2018 (Guthy-Jackson Charitable Foundation) Multiple Sclerosis vs NMO Pittock and Lucchinetti 2016 History 1894: Clinical case descriptions 2004: AQP4 antibody identified by Devic and Gault by Lennon, Weinshenker et al. Eugene Devic (1858–1930) Lancet2004; 364: 2106–12; Journal of Neuroinflammation 2013, 10:8 Diagnostic Criteria Wingerchuk et al. 2015 Myelin Oligodendrocyte (MOG) Antibody ▪ More common in men and whites ▪ Bilateral optic neuritis, caudal myelitis ▪ Better recovery compared to AQP4-Ab pos NMO ▪ MRI brain without NMO findings ▪ Assay now commercially available at Mayo Sato et al. 2014; van Pelt et al. 2016 Auto-Antibody to Aquaporin 4 Water channel protein in ▪ Astrocytic foot processes at the blood-brain barrier ▪ Spinal cord grey matter ▪ Periaqueductal and periventricular regions ▪ Mueller cells in the retina Amiry-Moghaddam and Otterson 2003 Bystander Oligodendrocyte Injury Tradtrantip et al 2017 Pathology Extensive demyelination Perivascular & parenchymal Complement activation Axonal injury, necrosis eosinophils & granulocytes rosette and rim pattern Jacob et al.
    [Show full text]
  • HY 2021 Results
    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Biologic Immunomodulators Pa Summary
    GEORGIA MEDICAID FEE-FOR-SERVICE BIOLOGIC IMMUNOMODULATORS PA SUMMARY Preferred Non-Preferred Arcalyst (rilonacept) Actemra Subcutaneous (tocilizumab) Benlysta subcutaneous (belimumab) Cimzia (certolizumab) Enbrel (etanercept) Cosentyx (secukinumab) Humira (adalimumab) Dupixent (dupilumab) Ilaris (canakinumab) Enspryng (satralizumab-mwge) Xeljanz (tofacitinib) Fasenra Pen (benralizumab autoinjector) Xeljanz XR (tofacitinib extended-release) Kevzara (sarilumab) Kineret (anakinra) Nucala Pen (mepolizumab autoinjector) Olumiant (baricitinib) Orencia Subcutaneous (abatacept) Otezla (apremilast) Rinvoq (upadacitinib) Siliq (brodalumab) Simponi (golimumab) Stelara (ustekinumab) Skyrizi (risankizumab) Taltz (ixekizumab) Tremfya (guselkumab) The drug names above include all available oral or subcutaneous formulations under the same primary name. LENGTH OF AUTHORIZATION: Varies NOTES: ▪ All preferred and non-preferred products require prior authorization. Intravenous (IV) formulations of the biologic immunomodulators are not covered under Pharmacy Services. ▪ The criteria details below are for the outpatient pharmacy program. If a medication is being administered in a physician’s office or clinic, then the medication must be billed through the DCH physician services program and not the outpatient pharmacy program. Information regarding the physician services program is located at www.mmis.georgia.gov. PA CRITERIA: Actemra Subcutaneous ❖ Approvable for members 2 years of age or older with a diagnosis of moderately to severely active polyarticular
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • An Interleukin-6 Receptor-Blocking Therapy for Neuromyelitis Optica Spectrum Disorder
    Review Neuroimmunology Satralizumab: An Interleukin-6 Receptor-blocking Therapy for Neuromyelitis Optica Spectrum Disorder Norio Chihara,1 Riki Matsumoto1 and Takashi Yamamura2 1. Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Japan; 2. Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan euromyelitis optica spectrum disorder (NMOSD) is a relapsing inflammatory disease of the central nervous system in which even a single disease flare may result in persistent neurological disability. The core group of patients with NMOSD, characterized by Nprominent astrocyte pathology, has high levels of autoantibodies reactive to aquaporin-4 (AQP4), a water channel expressed on astrocytes. In these patients, activation of autoreactive T and B cells, production of AQP4 autoantibody (AQP4-Ab) and AQP4-Ab-mediated complement-dependent destruction of astrocytes are presumed be the critical events in the pathology. Recent clinical trials have shown the efficacy of therapeutic antibodies targeting complement C5, interleukin-6 receptor (IL-6R) and CD19+ B cells in patients with NMOSD, particularly those with AQP4-Ab seropositivity. Regarding the pathogenesis of NMOSD, prior studies have indicated that IL-6 promotes the activation of autoreactive T cells, prolongs the survival of AQP4-Ab-producing B cells and inhibits blood–brain barrier integrity. The results of two pivotal clinical trials showing the efficacy of satralizumab have firmly established the role of IL-6 and IL-6R signalling in the pathogenesis of AQP4-Ab-positive NMOSD. This review aims to evaluate the involvement of IL-6 in NMOSD and the potential of satralizumab, a humanized antibody against IL-6R, in the current and future practice of NMOSD.
    [Show full text]
  • CHMP Agenda of the 19-22 April 2021 Meeting
    28 July 2021 EMA/CHMP/220334/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 19-22 April 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 19 April 2021, 09:00 – 19:30, virtual meeting/ room 1C 20 April 2021, 08:30 – 19:30, virtual meeting/ room 1C 21 April 2021, 08:30 – 19:30, virtual meeting/ room 1D 22 April 2021, 08:30 – 19:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 8.1.1 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Medical Drug Benefit Clinical Criteria Updates
    Medicaid Managed Care Provider Bulletin April 2021 Medical drug benefit Clinical Criteria updates On August 16, 2019, November 15, 2019, December 18, 2019, February 21, 2020, March 26, 2020, May 15, 2020, June 18, 2020, August 21, 2020, September 24, 2020, and November 20, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Healthy Blue. These policies were developed, revised or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: • New: newly published criteria • Revised: addition or removal of medical necessity requirements, new document number • Updates marked with an asterisk (*): criteria may be perceived as more restrictive Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services. Effective date Document number Clinical Criteria title New or revised 06/07/2021 ING-CC-0154* Givlaari (givosiran) New 06/07/2021 ING-CC-0155* Ethyol (amifostine) New 06/07/2021 ING-CC-0156* Reblozyl (luspatercept) New 06/07/2021 ING-CC-0157* Padcev (enfortumab vedotin) New 06/07/2021 ING-CC-0158* Enhertu (fam-trastuzumab deruxtecan-nxki) New 06/07/2021 ING-CC-0159* Scenesse (afamelanotide) New 06/07/2021 ING-CC-0161* Sarclisa (isatuximab-irfc) New
    [Show full text]
  • Medical Drug Benefit Clinical Criteria Updates
    Provider Bulletin November 2020 Medical drug benefit Clinical Criteria updates On August 21, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Healthy Blue. These policies were developed, revised or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: New: newly published criteria Revised: addition or removal of medical necessity requirements, new document number Annual review: minor wording and formatting updates, new document number Updates marked with an asterisk (*): criteria may be perceived as more restrictive Please share this notice with other members of your practice and office staff. Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services. Effective date Document number Clinical Criteria title New, revised, annual review 12/28/2020 ING-CC-0170* Uplizna (inebilizumab) New 12/28/2020 ING-CC-0172* Viltepso (viltolarsen) New 12/28/2020 ING-CC-0173* Enspryng (satralizumab-mwge) New 12/28/2020 ING-CC-0174* Kesimpta (ofatumumab) New 12/28/2020 ING-CC-0168* Tecartus (brexucabtagene autoleucel) New 12/28/2020 ING-CC-0171* Zepzelca (lurbinectedin) New Phesgo (pertuzumab/trastuzumab/ 12/28/2020 ING-CC-0169* New hyaluronidase-zzxf)
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • Self-Administered Specialty Drug List
    Self‐Administered Drug List BRAND NAME GENERIC DRUG NME ABIRATERONE ACETATE ABIRATERONE ACETATE ACTEMRA TOCILIZUMAB ACTEMRA ACTPEN TOCILIZUMAB ACTHAR CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA‐1B,RECOMB ADCIRCA TADALAFIL ADEMPAS RIOCIGUAT AFINITOR EVEROLIMUS AFINITOR DISPERZ EVEROLIMUS ALECENSA ALECTINIB HCL ALUNBRIG BRIGATINIB ALYQ TADALAFIL AMBRISENTAN AMBRISENTAN AMPYRA DALFAMPRIDINE APOKYN APOMORPHINE HCL ARANESP DARBEPOETIN ALFA IN POLYSORBAT ARCALYST RILONACEPT ARIKAYCE AMIKACIN LIPOSOMAL/NEB.ACCESSR ARIXTRA FONDAPARINUX SODIUM AUBAGIO TERIFLUNOMIDE AUSTEDO DEUTETRABENAZINE AVEED TESTOSTERONE UNDECANOATE AVONEX INTERFERON BETA‐1A AVONEX INTERFERON BETA‐1A/ALBUMIN AVONEX PEN INTERFERON BETA‐1A AYVAKIT AVAPRITINIB BAFIERTAM MONOMETHYL FUMARATE BALVERSA ERDAFITINIB BENLYSTA BELIMUMAB BETASERON INTERFERON BETA‐1B BETHKIS TOBRAMYCIN BOSENTAN BOSENTAN BOSULIF BOSUTINIB BRAFTOVI ENCORAFENIB BRONCHITOL MANNITOL BRUKINSA ZANUBRUTINIB BYNFEZIA OCTREOTIDE ACETATE CABENUVA CABOTEGRAVIR/RILPIVIRINE CABLIVI CAPLACIZUMAB‐YHDP CABOMETYX CABOZANTINIB S‐MALATE CALQUENCE ACALABRUTINIB CAPECITABINE CAPECITABINE CAPRELSA VANDETANIB CARBAGLU CARGLUMIC ACID CAYSTON AZTREONAM LYSINE CERDELGA ELIGLUSTAT TARTRATE CETROTIDE CETRORELIX ACETATE CHENODAL CHENODIOL CHOLBAM CHOLIC ACID CHORIONIC GONADOTROPIN CHORIONIC GONADOTROPIN, HUMAN CIMZIA CERTOLIZUMAB PEGOL COPAXONE GLATIRAMER ACETATE COPIKTRA DUVELISIB COSENTYX (2 SYRINGES) SECUKINUMAB COSENTYX PEN SECUKINUMAB COSENTYX PEN (2 PENS) SECUKINUMAB COSENTYX SYRINGE SECUKINUMAB COTELLIC COBIMETINIB FUMARATE CYSTADANE
    [Show full text]
  • (CHMP) Agenda for the Meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    22 March 2021 EMA/CHMP/171652/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 22 March 2021, 09:00 – 19:30, virtual meeting/ room 1C 23 March 2021, 08:30 – 19:30, virtual meeting/ room 1C 24 March 2021, 08:30 – 19:30, virtual meeting/ room 1C 25 March 2021, 08:30 – 19:30, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]